2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
243
Neoplasms
17
Neoplasm Metastasis
15
Carcinoma, Intraductal, Noninfiltrating
11
Breast Diseases
8
Advanced Breast Cancer
8
Breast Neoplasms, Male
7
Breast Carcinoma In Situ
7
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Arthralgia
5
Neoplasms by Site
3
Breast Cancer Metastatic
3
Uterine Cervical Neoplasms
2
Recurrence
2
Patient Compliance
2
Osteoporosis
2
Obesity
2
Multiple Endocrine Neoplasia Type 1
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasm Female
2
Vitamin D Deficiency
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Seizures
1
Sarcoma
1
Interventions
Cisplatin
281
pembrolizumab
234
Radiotherapy
171
Cetuximab
169
Carboplatin
123
Docetaxel
110
Paclitaxel
96
Fluorouracil
95
Nivolumab
88
Radiotherapy, Intensity-Modulated
80
Magnetic Resonance Spectroscopy
39
durvalumab
36
Radiation
33
Surgical Procedures, Operative
32
Drug Therapy
32
Biopsy
28
Radiosurgery
25
Erlotinib Hydrochloride
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Specimen Handling
22
Platinum
22
Immunohistochemistry
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Chemoradiotherapy
19
Capecitabine
19
tremelimumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Anastrozole
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled